Development of antigen-specific memory CD8+ T cells following live-attenuated chimeric West Nile virus vaccination
Smith, Heidi L. ; Monath, Thomas P. ; Pazoles, Pamela P. ; Rothman, Alan L. ; Casey, Diane M. ; Terajima, Masanori ; Ennis, Francis A. ; Guirakhoo, Farshad ; Green, Sharone
Citations
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Publication Date
Keywords
CD8-Positive T-Lymphocytes
Chemokine CCL4
Epitopes, T-Lymphocyte
Human Experimentation
Humans
Immunologic Memory
Interferon-gamma
Placebos
T-Lymphocyte Subsets
Tumor Necrosis Factor-alpha
Vaccination
Vaccines, Attenuated
Viral Envelope Proteins
West Nile Virus Vaccines
West Nile virus
Life Sciences
Medicine and Health Sciences
Women's Studies
Subject Area
Embargo Expiration Date
Link to Full Text
Abstract
ChimeriVax-WN02 is a novel live-attenuated West Nile virus (WNV) vaccine containing modified WNV premembrane (prM) and envelope (E) sequences inserted into the yellow fever 17D vaccine genome. We investigated the induction and evolution of CD8(+) T cell responses to a WNV envelope epitope, which is a dominant target in naturally infected HLA-A*02-positive individuals. WNV epitope-specific CD8(+) T cells were detected by HLA tetramer staining in 22 of 23 donors tested, with peak frequencies occurring between days 14 and 28. WNV epitope-specific T cells evolved from an effector phenotype to a long-lived memory phenotype. In the majority of donors, CD8(+) T cells were able to lyse targets expressing WNV envelope protein and produced macrophage inflammatory protein 1ss, interferon gamma, and/or tumor necrosis factor alpha following envelope peptide stimulation. WNV E-specific CD8(+) T cell responses were detected for up to 1 year after vaccination. The evolution of this WNV-specific T cell response is similar to that observed in established, highly immunogenic vaccines.
Source
J Infect Dis. 2011 Feb 15;203(4):513-22. Epub 2011 Jan 7. Link to article on publisher's site